The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1
Open accessAbstract
PURPOSE To determine whether differences in baseline lesion size and visual acuity might explain differing results found in three different lesion compositions (predominantly classic, minimally classic, and occult with no classic) among three placebo-controlled, randomized clinical trials evaluating photodynamic therapy with verteporfin (Visudyne, Novartis AG), also termed verteporfin therapy, in patients with subfoveal choroidal neovascularization (CNV) due to age-related macular degeneration (AMD). METHODS Exploratory analyses were conducted in patients with predominantly classic or minimally classic lesions at enrollment in the Treatment of AMD with Photodynamic Therapy (TAP) Investigation and in AMD patients with occult with no classic CNV in the Verteporfin In Photodynamic Therapy (VIP) Trial. Baseline characteristics of patients among these three lesion compositions were compared. In addition, multiple linear regression modeling was used to explore the effect of baseline lesion size, visual acuity, and lesion composition on mean change in visual acuity from baseline to 24 months. RESULTS At baseline, the mean size of predominantly classic lesions (3.4 disk areas) was smaller than that of minimally classic (4.7 disk areas) and occult with no classic lesions (4.3 disk areas). In the multiple linear regression model of individual lesion compositions, there was a significant treatment-by-lesion-size interaction for minimally classic and occult with no classic lesions, but not for predominantly classic lesions. Interaction between treatment and baseline visual acuity was not significant for any lesion composition. Small verteporfin-treated lesions lost less vision than large verteporfin-treated lesions in each lesion composition. In the multiple linear regression model that included all lesion compositions, lesion size was a more significant predictive factor for the magnitude of treatment benefit than either lesion composition or visual acuity. Smaller (4.0 disk areas or less) minimally classic and occult with no classic lesions had similar visual acuity outcomes to those observed in predominantly classic lesions. CONCLUSIONS Based on exploratory analyses, lesion size in the TAP Investigation and VIP Trial was an important predictor of the magnitude of treatment benefit with verteporfin therapy in occult with no classic and minimally classic lesion compositions. In patients with AMD, treating smaller rather than larger neovascular lesions, regardless of lesion composition, likely will result in a better level of visual acuity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
(2001) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(01)00967-9 · Cited by 814
Photocoagulation for Diabetic Macular Edema
Aiello, L. M., & Ferris, F. L. (1987) · Archives of Ophthalmology · doi:10.1001/archopht.1987.01060090021004 · Cited by 733
Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin
(2001) · Ophthalmology · doi:10.1016/s0161-6420(01)00544-9 · Cited by 546
(1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080090044025 · Cited by 495
VERTEPORFIN ROUNDTABLE 2000 AND 2001 PARTICIPANTS, T. O. A.-R. M. D. W. P. T. (. S. G. P. I. (2002) · Retina · doi:10.1097/00006982-200202000-00003 · Cited by 246
(2002) · Archives of Ophthalmology · doi:10.1001/archopht.120.11.1443 · Cited by 178
McClure, M., Hart, P. M., Jackson, A. J., Stevenson, M. R., & Chakravarthy, U. (2000) · British Journal of Ophthalmology · doi:10.1136/bjo.84.3.244 · Cited by 157
Cited by
Vascular endothelial growth factor in eye disease
Penn, J. S., Madan, A., Caldwell, R. B., Bartoli, M., Caldwell, R. W., & Hartnett, M. E. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.001 · Cited by 762
The Natural History and Prognosis of Neovascular Age-Related Macular Degeneration
Wong, T., Chakravarthy, U., Klein, R., Mitchell, P., Zlateva, G., Buggage, R., Fahrbach, K., Probst, C., & Sledge, I. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.008 · Cited by 601
Koh, A., Lee, W. K., Chen, L.-J., Chen, S.-J., Hashad, Y., Kim, H., Lai, T. Y., Pilz, S., Ruamviboonsuk, P., Tokaji, E., et al. (2012) · Retina · doi:10.1097/iae.0b013e31824f91e8 · Cited by 587
Subgroup Analysis of the MARINA Study of Ranibizumab in Neovascular Age-Related Macular Degeneration
Boyer, D. S., Antoszyk, A. N., Awh, C. C., Bhisitkul, R. B., Shapiro, H., & Acharya, N. R. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2006.10.045 · Cited by 390
Freund, K. B., Zweifel, S. A., & Engelbert, M. (2010) · Retina · doi:10.1097/iae.0b013e3181e7976b · Cited by 386
Metadata
- Venue
- American Journal of Ophthalmology
- Publisher
- Elsevier BV
- Published
- 2003-09
- Volume
- 136
- Issue
- 3
- Pages
- 407-418
- ISSN
- 0002-9394 (ISSN-L)
- OpenAlex
- W2149579095
- Cited by
- 274
- References
- 8
- FWCI
- 33.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. https://app.cochat.ai/papers/10.1016/s0002-9394(03)00223-x
- The paper
- Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report no. 1. (2003). American Journal of Ophthalmology. https://doi.org/10.1016/s0002-9394(03)00223-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.